Richard Lopez, MD
Medical Oncologist
Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Photodynamic Therapy Targeted Therapy
Dr. Richard Lopez graduated the medical school from Stanford University School of Medicine and completed his residency program at the same university. He is specialized in Medical Oncology and also board certified in Medical Oncology. Dr. Lopez has been in practice for more than 20 years and is affiliated with University of Alabama Hospital. During his career, he has contributed to several publications of medical interest.
Stanford University
Medical School
Stanford University
Internship
American Board of Internal Medicine - Oncology
LKB1 reduces ROS-mediated cell damage via activation of p38.
Xu, H. G.,Zhai, Y. X.,Chen, J.,Lu, Y.,Wang, J. W.,Quan, C. S.,Zhao, R. X.,Xiao, X.,He, Q.,Werle, K. D.,Kim, H. G.,Lopez, R.,Cui, R.,Liang, J.,Li, Y. L.,Xu, Z. X.; Oncogene. 2014 Sep 30.
See more >>Alemtuzumab for the prevention and treatment of graft-versus-host disease.
January, C.T., Makielski, J.C., Duff, H.; Int J Hematol. 2011 May.
See more >>